NHS Approves Groundbreaking Teplizumab Treatment That Delays Type 1 Diabetes Onset by Three Years
England becomes the first country in Europe to approve teplizumab, a disease-modifying therapy that can delay the onset of type 1 diabetes by nearly three years in eligible patients.